The article highlights three UK-listed, AI-driven healthcare stocks, while noting that its screen surfaced five more players that are not covered. Haleon sells over-the-counter consumer health brands and uses Microsoft-powered data tools to guide product development and consumer targeting, with revenue of about £3.8b in North America, £2.6b in APAC and £4.7b in EMEA and Latam, and a market value near £33b. Its productivity and AI programme has already delivered 140 basis points of gross margin improvement. Abingdon Health brings AI into diagnostics through its Appdx smartphone reader, earning about £5 million from contract development and £4.1 million from regulatory services, with a market value near £39 million. AstraZeneca generates about $61.4b from pharmaceuticals, has a market value near £193b, and applies AI within its oncology and drug development work. The article also says AI projects that depend heavily on hardware can stall when financing or public support weakens, while software that helps doctors may scale with fewer physical bottlenecks.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
artificial intelligencehealthcareUK
Open a keyword to see other news on the same topic.
Related news
- Long Châu Named 'Asia's Outstanding Enterprise' for a Second Consecutive Year
Long Châu received the Corporate Excellence Award (Asia's Outstanding Enterprise) at the Asia Pacific Enterprise Awards (APEA) 2026, organized by Enterprise Asia, marking its second consecutive year of recognition. The judges cited its efforts in system development, technology innovation, governance, human resources and community activities. The chain has nearly 3,000 pharmacies and more than 240 vaccination centers across 34 provinces and cities, served by more than 22,000 healthcare professionals and more than 36 million loyal customers. The article also describes its use of AI and big data, partnerships with authorities and medical partners, and a long-term health program signed on 13 October with 16 multinational pharmaceutical companies.
- Microsoft exits data centre deal in blow to UK AI ambitions
Microsoft has confirmed it has withdrawn from a deal with British start-up Nscale to lease computing capacity at a planned AI data centre in Loughton, northeast of London, a setback for the UK's AI ambitions. The company said the decision relates to a single site and that it remains committed to its partnership with Nscale. Nscale said it is still committed to the Loughton project and is exploring alternative power sources, after UK media reported the site would not have power until the 2030s due to grid connection delays. Ahead of a planned New York IPO targeting a valuation of up to $35 billion, Nscale said its committed revenue relies heavily on Microsoft and Anthropic. The article also notes that OpenAI earlier withdrew from a UK Stargate partnership, citing high energy costs and regulatory uncertainty.
- 3 UK Grid Stocks Retail Investors Are Watching for AI Data Centre Power
Microsoft's decision to pull its anchor AI data centre deal with Nscale highlights the UK power grid, which electricity networks and equipment providers control. The article profiles three companies from a screen that surfaced 26 more. Drax Group, a major UK renewable generator with a market cap of about £2.6 billion, is building over 700MW of battery storage backed by around £500 million of committed capital. Volex, valued at about £1.2 billion, supplies data centre power cables and high-speed connectivity products, including products up to 800 gigabits per second. Invinity Energy Systems, with about £9 million of battery revenue and a £101 million market cap, faces a key risk in securing vanadium raw materials for its flow batteries.
- Is UnitedHealth Group Stock a Buy After Another Solid Quarter?
UnitedHealth beat expectations in Q3, with revenue of $112.7 billion (versus $113.2 billion a year earlier and $111.4 billion expected) and adjusted EPS of $4.69 against Wall Street's $4.14 estimate. The company raised its full-year adjusted EPS guidance to at least $20.50, from the previous $19.50 to $20, helped by exiting unprofitable markets and investing in AI. The stock closed just over $401 last week and is up around 22% in 2026, though its five-year returns remain negative. The article says the forward P/E of around 16 is below the more than 19 times that the average S&P 500 stock trades at, and the 2.3% dividend yield adds appeal for income investors. It concludes UnitedHealth remains a worthwhile option given its modest valuation and improving earnings.
- MSB Brings EVERGLOW Experience to M-First Female Customers
MSB held the EVERGLOW event at the M-First Lounge in its Head Office transaction branch to thank female Priority customers in the M-First segment on Vietnamese Women's Day, 20/10. The program featured 1:1 health consultations with the Hong Ngoc Medical System, talks by Phạm Thị Thùy Dương, director of the IVF centre, on health care, and by beauty expert Nguyễn Ngọc Nữ on skincare, along with hands-on activities such as a perfume-making workshop. MSB says the event is part of expanding its M-First privilege ecosystem, linking financial services with quality of life. A related health care program with Hong Ngoc runs from 01/10/2026 to 09/09/2027, offering check-up, screening and VIP benefits, with some benefits extended to members' family members.
- Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It
Warren Buffett, now chairman emeritus of Berkshire Hathaway, warned at the May shareholder meeting that 'we've never had people in a more gambling mood than now,' pointing to individuals rushing into short-term options and market bets. The article argues the S&P 500 and quality stocks have historically recovered from turmoil, and that pharma and biotech firms can hold up in tough times because patients always need treatment. It highlights three picks: Vertex Pharmaceuticals (VRTX), the cystic fibrosis leader that recently purchased Crinetics; Eli Lilly (LLY), whose tirzepatide brought in more than $14 billion of its $23 billion revenue in the recent quarter; and AbbVie (ABBV), where Rinvoq and Skyrizi each grew 24% and which is a Dividend King with more than 50 consecutive years of dividend increases.
Related markets
Latest news
- TRX Gold to Present at Red Cloud's Fall Mining Showcase 2026
TRX Gold will present at Red Cloud's Fall Mining Showcase 2026, an in-person conference at the Omni King Edward Hotel in Toronto on October 28 and 29, 2026. Stephen Mullowney is scheduled to present on Thursday, October 29, 2026 at 12:00 PM Eastern. The release describes the company as a gold producer advancing the Buckreef Gold Project in Tanzania, which includes an established open pit and a 2,000 tonnes per day plant. The May 2025 PEA outlines average annual gold production of 62,000 oz over 17.6 years.
- Tesla Stock vs. the S&P 500: Which Investment Wins Through 2030?
The article argues Tesla trades at roughly 203 times this year's expected earnings and 13 times expected sales, a valuation that looks very expensive given gross margin pressure and a slower-than-expected robotaxi rollout. The flying Roadster, slated for production in 2028, is unlikely to make a meaningful sales or earnings contribution before 2030. The author thinks a Tesla-SpaceX merger by the end of the decade, likely an all-stock deal, is more likely than not and would be a key factor in how Tesla stock performs against the S&P 500 through 2030.
- SpaceX surprises Wall Street with Oct. 20 earnings date — here's why
SpaceX (SPCX) will release earnings on Oct. 20 after the market close, a surprise since earnings dates are usually shared weeks in advance. Evercore ISI analyst Kutgun Maral says possible reasons include putting updated financials on record before new financing or getting ahead of major lock-up releases, though scheduling is also possible. Reuters reported SpaceX is seeking $40 billion in financing to buy advanced Nvidia AI chips, including about $10 billion in bank loans and $30 billion in investment-grade debt, with Apollo expected to lead. The lock-up schedule includes 1.30 billion shares two days after earnings, 329 million on 10/24, and a remaining 857 million tranche of the 180-day group.
- AEP Partners with Amazon and X-energy to Explore Advanced Nuclear Energy in Indiana
American Electric Power (AEP) has announced a joint development agreement with X-energy to evaluate the feasibility of a 960-megawatt advanced nuclear project at a former coal plant site in Sullivan County, Indiana. Amazon is supporting development through a funding agreement. If the project reaches a final investment decision and is built, Amazon intends to buy the power under a long-term contract covering the facility's costs and operations. The initial project would include 12 Xe-100 units of 80 MW each, and the companies say it could create jobs, expand the local tax base and strengthen the grid for more than 60 years. AEP says the agreements include the financial safeguards it considers essential for any nuclear project to move forward.
- Talamore Marks One Year at Coffee with Major Advances Toward a 2027 Construction Decision
Talamore Mining marks one year since closing its acquisition of the Coffee Gold Project in Yukon, Canada, from Newmont Corporation on October 17, 2025. The company has assembled a financing package of up to C$688 million, including a C$149.5 million equity offering, a C$450 million secured project debt facility and up to C$88 million from a warrant early-exercise program. A primary road permit received in August 2026 allows completion of the 214-kilometre Northern Access Route from Dawson City. The February 2026 Preliminary Economic Assessment outlined a 13-year open-pit heap leach mine with an after-tax NPV (5%) of US$2.3 billion and an after-tax IRR of 47.8%. G Mining Services is completing the Feasibility Study, expected in Q1 2027, ahead of a construction decision targeted for the first half of 2027.
- Tiger Gold Extends Mineralization to the South at Ceibal, Drilling 268 m @ 0.5 g/t Au from Surface
Tiger Gold reported assay results from hole CEDDH-023 at its Ceibal target within the Quinchía Gold Project in Colombia. The hole intersected 268 metres grading 0.5 g/t Au from surface, extending mineralization south into a previously untested part of the corridor. Mineralization remains open to the west and southwest, where additional holes are testing for extension, and assays from Ceibal and Tesorito are pending. The drilling is intended to support a maiden Mineral Resource estimate, targeted for near the end of Q1 2027.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.